Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

2,353JPY
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
¥2,353
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,114,370
52-wk High
¥2,748
52-wk Low
¥2,073

Chart for

About

Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Medical Supplies segment is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The... (more)

Overall

Beta: 0.26
Market Cap(Mil.): ¥1,459,125.00
Shares Outstanding(Mil.): 561.42
Dividend: 28.00
Yield (%): 2.00

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Mitsubishi Tanabe Pharma completes purchase of NeuroDerm

Oct 18Mitsubishi Tanabe Pharma Corp * Says it completed purchase of NeuroDerm Ltd * Purchase plan was announced on July 24 Source text in Japanese:https://goo.gl/LcG5Lm Further company coverage: (Beijing Headline News)

18 Oct 2017

BRIEF- Mitsubishi Tanabe Pharma sells drug sales unit

* Says it sold 100 percent stake in a drug sales unit to Nipro, on Oct. 1

02 Oct 2017

BRIEF-Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition

* Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation Source text for Eikon: Further company coverage:

01 Aug 2017

Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 billion

TOKYO/TEL AVIV Japan's Mitsubishi Tanabe Pharma Corp has agreed to buy Israeli drug maker Neuroderm for $1.1 billion in cash as part of a strategy to grow its business in the United States.

24 Jul 2017

UPDATE 3-Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

* Neuroderm shares up 15 pct in premarket trade (Adds Neuroderm shares up 15 pct in premarket trade)

24 Jul 2017

Japan's Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

TOKYO, July 24 Japan's Mitsubishi Tanabe Pharma Corp said on Monday it will acquire Israeli drug maker Neuroderm for $1.1 billion in an all-cash deal to expand its overseas business.

24 Jul 2017

BRIEF- Mitsubishi Chemical Holdings consolidated subsidiary to buy NeuroDerm for about $1.1 bln

* Says its consolidated subsidiary Mitsubishi Tanabe Pharma Corp will buy NeuroDerm Ltd, for about $1.1 billion (about 124.1 billion yen), $39 per share, effective October

24 Jul 2017

BRIEF-Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln

* Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash

24 Jul 2017

BRIEF-R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

12 Jun 2017

Earnings vs. Estimates